MARKET REPORT: Drug maker Summit Therapeutics shares double on news it won the rights to an exclusive drug

Drug maker Summit Therapeutics added almost £80million to its stock market value after it won the rights to an exclusive drug.
Shares nearly doubled in their best day since 2009, after it revealed it was teaming up with US rival Sarepta Therapeutics to develop and market a specialist drug in Europe.
The licence allows the AIM-listed company to sell an experimental treatment for muscle wasting disease Duchenne muscular dystrophy.
The fatal illness typically emerges in boyhood, causing weakness in the arms and legs and eventually the lungs and heart. 
The new drug is designed to increase... read more

4 October 2016 in Business, Views: 41
Source: Daily Mail

News Widget for Webmasters

Realtime News


Mo Tu We Th Fr Sa Su
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28